Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.

Stubbs MC, Burn TC, Sparks RB, Maduskuie T, Diamond S, Rupar M, Wen X, Volgina A, Zolotarjova N, Waeltz P, Favata M, Jalluri R, Liu H, Liu XM, Li J, Collins R, Falahatpisheh N, Polam P, DiMatteo D, Feldman P, Dostalik V, Thekkat P, Gardiner C, He X, Li Y, Covington M, Wynn R, Ruggeri B, Yeleswaram S, Xue C, Yao W, Combs AP, Huber R, Hollis G, Scherle P, Liu P.

Clin Cancer Res. 2018 Sep 11. pii: clincanres.0098.2018. doi: 10.1158/1078-0432.CCR-18-0098. [Epub ahead of print]

PMID:
30206163
2.

(S)-4-(3-18F-fluoropropyl)-L-glutamic acid: an 18F-labeled tumor-specific probe for PET/CT imaging--dosimetry.

Smolarz K, Krause BJ, Graner FP, Wagner FM, Hultsch C, Bacher-Stier C, Sparks RB, Ramsay S, Fels LM, Dinkelborg LM, Schwaiger M.

J Nucl Med. 2013 Jun;54(6):861-6. doi: 10.2967/jnumed.112.112581. Epub 2013 Apr 8.

3.

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.

Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, Li Y, Wynn R, Fridman JS, Burn TC, Combs AP, Newton RC, Scherle PA.

Blood. 2010 Apr 29;115(17):3520-30. doi: 10.1182/blood-2009-09-246124. Epub 2010 Mar 2.

4.

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.

Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, Burn TC, Waeltz P, Sparks RB, Yue EW, Combs AP, Scherle PA, Vaddi K, Fridman JS.

Mol Cancer Ther. 2010 Feb;9(2):489-98. doi: 10.1158/1535-7163.MCT-09-0628. Epub 2010 Feb 2.

5.

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS.

Neoplasia. 2010 Jan;12(1):28-38.

6.

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Liu PC, Caulder E, Li J, Waeltz P, Margulis A, Wynn R, Becker-Pasha M, Li Y, Crowgey E, Hollis G, Haley P, Sparks RB, Combs AP, Rodgers JD, Burn TC, Vaddi K, Fridman JS.

Clin Cancer Res. 2009 Nov 15;15(22):6891-900. doi: 10.1158/1078-0432.CCR-09-1298. Epub 2009 Nov 3.

7.

Design considerations for incorporating sodium iodide symporter reporter gene imaging into prostate cancer gene therapy trials.

Siddiqui F, Barton KN, Stricker HJ, Steyn PF, Larue SM, Karvelis KC, Sparks RB, Kim JH, Brown SL, Freytag SO.

Hum Gene Ther. 2007 Apr;18(4):312-22.

PMID:
17408358
8.

Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors.

Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PC, Combs AP.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):736-40. Epub 2006 Oct 28.

PMID:
17097290
9.

Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B.

Ala PJ, Gonneville L, Hillman M, Becker-Pasha M, Yue EW, Douty B, Wayland B, Polam P, Crawley ML, McLaughlin E, Sparks RB, Glass B, Takvorian A, Combs AP, Burn TC, Hollis GF, Wynn R.

J Biol Chem. 2006 Dec 8;281(49):38013-21. Epub 2006 Oct 6.

10.

A theoretical investigation into post-operative, intracavitary beta therapy of high-grade glioblastomas using yttrium-90.

Stefanou SS, Sparks RB, Dale RG.

Phys Med Biol. 2006 Oct 21;51(20):5377-89. Epub 2006 Oct 3.

PMID:
17019045
11.

Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.

Combs AP, Zhu W, Crawley ML, Glass B, Polam P, Sparks RB, Modi D, Takvorian A, McLaughlin E, Yue EW, Wasserman Z, Bower M, Wei M, Rupar M, Ala PJ, Reid BM, Ellis D, Gonneville L, Emm T, Taylor N, Yeleswaram S, Li Y, Wynn R, Burn TC, Hollis G, Liu PC, Metcalf B.

J Med Chem. 2006 Jun 29;49(13):3774-89.

PMID:
16789735
12.

Blood-based red marrow dosimetry: where's the beef?

Siegel JA, Sparks RB, Sharkey RM, Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Meredith RF, Sgouros G, Stabin MG.

J Nucl Med. 2005 Aug;46(8):1404-6; author reply 1405-6. No abstract available.

13.
14.
15.

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.

Wiseman GA, Leigh BR, Erwin WD, Sparks RB, Podoloff DA, Schilder RJ, Bartlett NL, Spies SM, Grillo-López AJ, Witzig TE, White CA.

Cancer Biother Radiopharm. 2003 Apr;18(2):165-78.

PMID:
12804042
16.

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.

J Nucl Med. 2003 Mar;44(3):465-74.

17.

Total-body and red marrow dose estimates.

Siegel JA, Stabin MG, Sparks RB.

J Nucl Med. 2003 Feb;44(2):320-1; author reply 321-3. No abstract available.

18.

Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.

Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD.

J Nucl Med. 2003 Jan;44(1):67-76.

19.

Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters.

Stabin MG, Siegel JA, Sparks RB.

Cancer Biother Radiopharm. 2002 Oct;17(5):535-43.

PMID:
12470423
20.
21.

Radiation dose distributions in normal tissue adjacent to tumors containing (131)I or (90)Y: the potential for toxicity.

Sparks RB, Crowe EA, Wong FC, Toohey RE, Siegel JA.

J Nucl Med. 2002 Aug;43(8):1110-4.

22.

Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.

Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, Silverman DH, Witzig TE, Sparks RB, White CA.

Cancer. 2002 Feb 15;94(4 Suppl):1349-57.

23.
24.

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR.

Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):181-94.

PMID:
11418315
25.

Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method.

Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB.

J Nucl Med. 2001 Mar;42(3):492-8.

26.

Radiation dosimetry of a 99mTc-labeled IgM murine antibody to CD15 antigens on human granulocytes.

Mozley PD, Stubbs JB, Dresel SH, Barraclough ED, Smith T, Patel M, Finkelman C, Sparks RB, Thakur ML, Mathur A, Alavi A.

J Nucl Med. 1999 Apr;40(4):625-30.

27.
28.

Radiation absorbed dose to the embryo/fetus from radiopharmaceuticals.

Russell JR, Stabin MG, Sparks RB, Watson E.

Health Phys. 1997 Nov;73(5):756-69.

PMID:
9378651
29.

Placental transfer of radiopharmaceuticals and dosimetry in pregnancy.

Russell JR, Stabin MG, Sparks RB.

Health Phys. 1997 Nov;73(5):747-55.

PMID:
9378650
30.
31.

Evidence for an inactive plasma membrane-associated precursor of active cytoplasmic ornithine decarboxylase in developing embryos of Musca domestica.

Lilleberg SL, Killilea SD, Vaske DA, Leopold RA, Sparks RB Jr.

Biochem Biophys Res Commun. 1991 Jan 31;174(2):497-503.

PMID:
1993050
32.
33.

Patterns of urease synthesis in developing soybeans.

Polacco JC, Sparks RB.

Plant Physiol. 1982 Jul;70(1):189-94.

34.

Bidirectional replication of the mini-ColE1 plasmid pVH51.

Eichenlaub R, Sparks RB, Helinski DR.

J Bacteriol. 1979 Apr;138(1):257-60.

35.

Association of cellular membrane of E. coli minicells with the origins/terminus region of replication of plasmid ColEl DNA.

Sparks RB Jr, Helinski DR.

Nature. 1979 Feb 15;277(5697):572-4. No abstract available.

PMID:
368651
37.

Purification and properties of an endonuclease from Chlamydomonas.

Small GD, Sparks RB Jr.

Arch Biochem Biophys. 1972 Nov;153(1):171-9. No abstract available.

PMID:
4346632
38.

Isolation of ultraviolet light induced pyrimidine dimers from enzymic hydrolyzates of DNA.

Small GD, Sparks RB.

Anal Biochem. 1971 May;41(1):116-25. No abstract available.

PMID:
4325337

Supplemental Content

Loading ...
Support Center